MST1 Inhibitors and Multiple Myeloma

These flashcards cover key terms and concepts related to MST1 inhibitors and the pathology of Multiple Myeloma.

Multiple Myeloma (MM)

A hematological malignancy characterized by abnormal clonal plasma cell growth in the bone marrow.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

An asymptomatic condition characterized by the presence of intact monoclonal immunoglobulins (M protein), which can remain benign.

Smoldering Multiple Myeloma (SMM)

An intermediate stage between MGUS and MM that is asymptomatic but has higher M protein levels and plasma cell infiltration.

Immunoglobulin Translocations

Genetic alterations that involve the immunoglobulin heavy locus which can lead to upregulation of oncogenes and contribute to disease progression in MM.

Cyclin D (CCND)

A protein that regulates the cell cycle and can be transcriptionally activated by IgH translocations in MM.

MYC Gene

A gene encoding transcription factors involved in cell proliferation, differentiation, and metabolism; often dysregulated in MM.

Epigenetic Silencing

A mechanism wherein gene expression is suppressed by changes that do not alter the DNA sequence, such as hypermethylation.

Autologous Stem Cell Transplant (ASCT)

A treatment approach for newly diagnosed MM patients that involves harvesting and transplanting the patient’s own stem cells.

Decitabine

A hypomethylating agent that acts as a prodrug, requiring conversion to its active form to incorporate into DNA and cause global hypomethylation.